

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-0155US1</b>	Application No. <b>10/564,665</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Reiko Irie et al.</b>	
		Filing Date <b>September 21, 2006</b>	Group Art Unit <b>1644</b>

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
	1	WO 03/046162	06/05/2003	WIPO			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	2	Hoon et al., "Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers." <i>Cancer Res.</i> , 53:5244-5250 (1993)
	3	Irie et al., "Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma." <i>Cancer Immunol. Immunother.</i> , 53:110-117 (2004)
	4	Youd et al., "Synergistic roles of IgM and complement in antigen trapping and follicular localization." <i>Eur. J. Immunol.</i> , 32:2328-2337 (2002)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	